Clinical Studies

Below are current clinical trials.

194 studies in Neurology and Neurosurgery (open studies only).

Filter this list of studies by location, status and more.

  1. Study of Trial Readiness in Cavernous Angiomas with Symptomatic Hemorrhage (CASH)

    1. Rochester, Minn.

    The purpose of this study is to set up the infrastructure for future clinical trials for patients with cavernous malformations. To do this we will be assessing the quality of MRI and data collection from patients with cavernous malformations across multiple sites in the country. At Mayo, we will be looking at new MRI "sequences" in addition to the usual sequences to see if that helps determine which cavernous malformations may bleed again.

  2. A Registry to Follow Long-Term Outcomes for Mother and Child Pairs After Fetal Surgery for Spina Bifida

    1. Rochester, Minn.

    The purpose of this study is to form a registry of data on the long term physical and mental health outcomes of the mother and child following fetal surgical repair for spina bifida.

  3. Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)

    1. Jacksonville, Fla.
    2. Rochester, Minn.

    We aim to determine whether cognitive impairment attributable to cerebral hemodynamic impairment in patients with high-grade asymptomatic carotid artery stenosis is reversible with restoration of flow. To accomplish this aim CREST-H will add on to the NINDS-sponsored CREST-2 trial (parallel, outcome-blinded Phase 3 clinical trials for patients with asymptomatic high-grade carotid artery stenosis which will compare carotid endarterectomy plus intensive medical management (IMM) versus IMM alone (n=1,240), and carotid artery stenting plus IMM versus IMM alone (n=1,240) to prevent stroke and death). CREST-H addresses the intriguing question of whether cognitive impairment can be reversed when it arises from abnormal cerebral hemodynamic perfusion in a hemodynamically impaired subset of the CREST-2 -randomized patients. We will enroll 500 patients from CREST-2, all of whom receive cognitive assessments at baseline and yearly thereafter. We anticipate identifying 100 patients with hemodynamic impairment as measured by an inter-hemispheral MRI perfusion "time to peak" (TTP) delay on the side of stenosis. Among those who are found to be hemodynamically impaired and have baseline cognitive impairment, the cognitive batteries at baseline and at 1 year will determine if those with flow failure who are randomized to a revascularization arm in CREST-2 will have better cognitive outcomes than those in the medical-only arm compared with this treatment difference for those who have no flow failure. We hypothesize that hemodynamically significant "asymptomatic" carotid disease may represent one of the few examples of treatable causes of cognitive impairment. If cognitive decline can be reversed in these patients, then we will have established a new indication for carotid revascularization independent of the risk of recurrent stroke.

  4. Arizona Parkinson's Disease Center Predictors of Parkinson’s Disease and Parkinson’s Disease-Associated Dementia

    1. Scottsdale/Phoenix, Ariz.

    The purpose of this study is ongoing longitudinal clinicopathologic studies of normal aging and Parkinson's Disease subjects. Specific projects of motor, non-motor and peripheral manifestations of Parkinson’s disease (PD) as possible early markers of PD onset in otherwise asymptomatic elderly people. Cognitive and non-cognitive markers of eventual dementia onset in previously non-demented persons with PD.

  5. A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

    1. Rochester, Minn.

    This is a multicenter, double-blind, parallel-group, placebo-controlled, study to assess the efficacy, safety, and PK of ZX008 when used as adjunctive therapy for uncontrolled seizures in pediatric and young adult subjects with Dravet syndrome. After an initial Screening and Baseline charting of seizure frequency, subjects who qualify for the study will be randomized (1:1:1) to receive either ZX008 (0.2 mg/kg/day, 0.8 mg/kg/day; maximum dose: 30 mg/day) or placebo. Randomization will be stratified by age group (< 6 years, ≥6 to 18 years). All subjects will be titrated to their randomized dose over a 14-day Titration Period. Following titration, subjects will continue treatment at their randomly assigned dose over a 12-week Maintenance Period. Subjects exiting the study will undergo a 2-week taper, unless they enroll in a follow-on study. Subjects will be followed for post-study safety monitoring. Parents/caregivers will use a diary daily to record the number/type of seizures, dosing, and use of rescue medication.

  6. Collection and Storage of DNA and Plasma in Patients with Dysautonomia and Healthy Controls

    1. Rochester, Minn.

    This study is being done to better understand the causes of autonomic disorders, and to collect and store DNA and plasma for future studies of autonomic disorders.

  7. Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

    1. Rochester, Minn.

    This study will evaluate the safety and efficacy of repeated administration of NurOwn® (MSC-NTF cells) therapy, which is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are enriched from the patient's own bone marrow, propagated ex vivo and induced to secrete Neurotrophic factors (NTFs). The autologous NurOwn® (MSC-NTF cells) are back-transplanted into the patient intrathecally by standard lumbar puncture where neurons and glial cells are expected to take up the neurotrophic factors secreted by the transplanted cells

  8. Acupuncture For The Treatment of Autonomic Dysfunction

    1. Jacksonville, Fla.

    The purpose of this study is to demonstrate the benefits of acupuncture in patients who have refractory autonomic dysfunction, including nausea, emesis, ileus, diabetic gastroparesis, failure to thrive.

  9. Normal and Pathological Aging

    1. Scottsdale/Phoenix, Ariz.

    This study is being done to learn more about possible ways in which the brain might stop working properly before the first signs of Alzheimer’s disease. In addition, it is hoped that the methods used to study and identify brain abnormalities before memory loss begins, will help to identify people who might benefit most from preventive therapy. It is also hoped that it will create a faster way to study new preventative treatments when they become available to test.

  10. Treating Patients with Dravet Syndrome Using ZX008 Expanded Access Protocol

    1. Rochester, Minn.

    The purpose of this study is to provide patients with Dravet Syndrome, who do not qualify for participation in one of the ongoing ZX008 clinical trials, to receive treatment.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. Next